The Placebo Effect in Cardiovascular Disease

Complementary and Integrative Therapies for Cardiovascular Disease

Volumn , Issue , 2005, Pages 2-28

  Frishman, William H ^a   Wolff, Andrew I ^b   Lee, Wei Nchih ^a   Peterson, Stephen J ^a   Glasser, Stephen P ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 13444312685     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03002-1.50005-7     Document Type: Chapter

References (93)

1. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994, 271:1609-1614.
2. Talbot M: The placebo prescription, New York Times Magazine January 9, 2000.
3. Weiner M, Weiner GJ The kinetics and dynamics of responses to placebo. Clin Pharmacol Ther 1996, 60:247-254.
4. Packer M, Medina N, Yushak M Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation 1985, 71:76l-766.
5. Melmon and Morrelli's clinical pharmacology: basic principles in therapeutics 2000, McGraw-Hill, New York. ed 4. S.G. Carruthers (Ed.).
6. Chalmers TC Prophylactic treatment of Wilson's disease. N Engl J Med 1968, 278:910-911.
7. Stedman's Medical Dictionary 1995, Williams & Wilkins, Baltimore. ed 26.
8. Shapiro AK Factors contributing to the placebo effect: their implications for psychotherapy. Am J Psychother 1961, 18:73.
9. Byerly H Explaining and exploiting placebo effects. Perspect Biol Med 1976, 19:423-436.
10. Lind JA: A treatise of the scurvy, Edinburgh, 1753.
11. Hill AB The clinical trial. Br Med Bull 1951, 7:278.
12. Beecher HK The powerful placebo. JAMA 1955, 159:1602.
13. Lasagna L, Masteller F, von Felsinger JM, Beecher HK A study of the placebo response. Am J Med 1954, 16:770.
14. The Coronary Drug Project Research Group: Influence of adherence to treatment and response to cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980, 303:1038-1041.
15. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990, 336:542-545.
16. Gallagher EJ, Viscoli CM, Horwitz RI The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993, 270:742-744.
17. Kaptchuk TJ The placebo effect in alternative medicine: Can the performance of a healing ritual have clinical significance?. Ann Intern Med 2002, 136:817-825.
18. Preston RA, Materson BJ, Reda DJ, Williams DW Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med 2000, 160:1449-1454.
19. Barsky AJ, Saintfort R, Rogers MP, Borus JF Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002, 287:622-627.
20. Feinstein AR: The placebo effect. In Education of Health Professionals in Complementary/Alternative Medicine. Conference sponsored by Josiah Macy Jr. Foundation, Phoenix, AZ, November 2-5, 2000. Published by Josiah Macy Jr. Foundation, New York, New York, 2001.
21. Wolf S, Pinsky RH Effects of placebo administration and occurrence of toxic reactions. JAMA 1954, 155:339.
22. Davis JM Don't let placebos fool you. Postgrad Med 1990, 88:21-24.
23. Moerman DE, Jonas WB Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002, 136:471-476.
24. Hahn RA The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 1997, 26:607-611.
25. Nies AS Principles of therapeutics. Goodman and Gilman's Pharmacological Basis of Therapeutics 2001, 45-66. McGraw Hill, New York. ed 10. J.G. Hardman, L.E. Limbird (Eds.).
26. Clark PI, Leaverton PE Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health 1994, 15:19-38.
27. FDA Draft: Guidelines for the Clinical Evaluation of Anti-anginal Drugs, January 10, 1989.
28. Hrobjartsson A, Gotzsche PC Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001, 344:1594-1602.
29. Amsterdam EA, Wolfson S, Gorlin R New aspects of the placebo response in angina pectoris. Am J Cardiol 1969, 24:305-306.
30. Kim MC, Kini A, Sharma SK Refractory angina pectoris: mMechanism and therapeutic options. J Am Coll Cardiol 2002, 39:923-934.
31. Glasser SP, Clark PI, Lipicky RJ, et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA 1991, 265:1550-1554.
32. Boissel JP, Philippon AM, Gauthier E, et al. Time course of long-term placebo therapy effects in angina pectoris. Eur Heart J 1986, 7:1030-1036.
33. McGraw BF, Hemberger JA, Smith AL, Schroeder JS Variability of exercise performance during long-term placebo treatment. Clin Pharmacol Ther 1981, 30:321-327.
34. Acute and chronic antianginal efficacy and continuous 24-hour application of transdermal nitroglycerin. Am J Cardiol 1991, 68:1263-1273. Transdermal Nitroglycerin Cooperative Study Group Steering Committee.
35. Deanfield JE, Detry JRG, Lichen PR, et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial). J Am Coll Cardiol 1994, 24:1460-1467. for the CAPE Study Group.
36. Beecher HK Surgery as a placebo: a quantitative study in bias. JAMA 1961, 176:1102.
37. Dimond EG, Kittle CF, Crockett JE Comparison of internal mammary artery ligation and sham operation for angina pectoris. Am J Cardiol 1960, 5:484.
38. Cobb LA Evaluation of internal mammary artery ligation by double-blind technique. N Engl J Med 1959, 260:1115.
39. Carver JR, Samuels F Sham therapy in coronary artery disease and atherosclerosis. Pract Cardiol 1988, 14:81.
40. van Rij AM, Solomon C, Packer SGK, Hopkins WG Chelation therapy for intermittent claudication. Circulation 1994, 90:1194-1199.
41. Enserink M Psychiatry: Are placebo-controlled drug trials ethical?. Science 2000, 288:416.
42. Halpern SD, Karlawish JHT Placebo-controlled trials are unethical in clinical hypertension research. Arch Intern Med 2000, 160:3167-3169.
43. Rothman KJ, Michels KB The continuing unethical use of placebo controls. N Engl J Med 1994, 331:394-398.
44. Frishman WH, Lee W-N, Glasser SP, et al. The placebo effect in cardiovascular disease. Cardiovascular Pharmacotherapeutics 2003, 15-25. McGraw Hill, New York. ed 2. W.H. Frishman, E.H. Sonnenblick, D.A. Sica (Eds.).
45. Packer M The placebo effect in heart failure. Am Heart J 1990, 120:1579-1582.
46. Russell SD, McNeer FR, Beere PA, et al. Improvement in the mechanical efficiency of walking: An explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. Am Heart J 1998, 135:107-114.
47. Archer TP, Leier CV Placebo treatment in congestive heart failure. Cardiology 1992, 81:125-133.
48. Pugsley DJ, Nassim M, Armstrong BK, Beilin L A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. Br J Clin Pharmacol 1979, 7:63-68.
49. Martin MA, Phillips CA, Smith AJ Acebutolol in hypertension: a double-blind trial against placebo. Br J Clin Pharmacol 1978, 6:351-356.
50. Report of Medical Research Council Working Party on Mild to Moderate Hypertension: Randomized controlled trial of treatment for mild hypertension: design and pilot trial. Br Med J 1977, 1:1437-1440.
51. Wilkinson PR, Raftery EB A comparative trial of clonidine, propranolol and placebo in the treatment of moderate hypertension. Br J Clin Pharmacol 1977, 4:289-294.
52. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967, 202:1028-1034. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
53. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 90 through 114 mm Hg. JAMA 1970, 213:1143-1152. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
54. Goldring W, Chasis H, Schreiner GE, Smith HW Reassurance in the management of benign hypertensive disease. Circulation 1956, 14:260.
55. Raftery EB, Gould BA The effect of placebo on indirect and direct blood pressure measurements. J Hypertens 1990, 8(Suppl 6):S93-100.
56. Mutti E, Trazzi S, Omboni S, et al. Effect of placebo on 24-h non-invasive ambulatory blood pressure. J Hypertens 1991, 9:361-364.
57. O'Brien E, Cox GP, O'Malley K Ambulatory blood pressure measurements in the evaluation of blood pressure lowering drugs. J Hypertens 1989, 7:243-247.
58. Coats AJS, Conway J, Somers VK, et al. Ambulatory blood pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther 1989, 3(Suppl 1):303-311.
59. Parati G, Pomidossi G, Casadei R, et al. Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. Am J Cardiol 1988, 61:27C-33C.
60. Casadei R, Parati G, Pomidossi G, et al. Twenty-four hour blood pressure monitoring: Evaluation of Spacelabs 5300 monitor by comparison with intra-arterial blood pressure recording in ambulant subjects. J Hypertens 1988, 6:797-803.
61. Portaluppi F, Strozzi C, degli Uberti E, et al. Does placebo lower blood pressure in hypertensive patients? A noninvasive chronobiological study. Jpn Heart J 1988, 29:189-197.
62. Sassano P, Chatellier G, Corvol P, Menard J Influence of observer's expectation on the placebo effect in blood pressure trials. Curr Ther Res 1987, 41:304.
63. Staessen JA, Thijs L, Bieniaszewski L, et al. On behalf of the Systolic Hypertension in Europe (SYST-EUR) Trial Investigators: ambulatory monitoring uncorrected for placebo overestimates long-term antihypertensive action. Hypertension 1996, 27(3 Pt 1):414-420.
64. Staessen JA, Fagard R, Thijis H Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet 1997, 350:757-763.
65. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. SHEP Cooperative Research Group.
66. Davis BR, Wittes J, Pressel S, et al. Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). Control Clin Trials 1993, 14:350-361.
67. Keane WF, Polis A, Wolf D, et al. The long-term tolerability of enalapril in hypertensive patients with renal impairment. Nephrol Dial Transplant 1997, 12(Suppl 2):75-81.
68. Michelson EL, Morganroth J Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. Circulation 1980, 61:690-695.
69. Morganroth J, Borland M, Chao G Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 1987, 59:97-99.
70. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406-412. The CAST Investigators.
71. Capone RJ, Pawitan Y, El-Sherif N, et al. Events in the Cardiac Arrhythmia Suppression Trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol 1991, 18:1434-1438. the CAST Investigators.
72. The Lipid Research Clinics Coronary Primary Prevention Trial Results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374. Lipid Research Clinics Program.
73. Glynn RJ, Buring JE, Manson JE, et al. Adherence to aspirin in the prevention of myocardial infarction: the Physicians' Heart Study. Arch Intern Med 1994, 154:2649-2657.
74. Cleophas TJM Clinical trials: design flaws associated with use of a placebo. Am J Ther 1996, 3:529.
75. Emanuel EJ, Miller F The ethics of placebo-controlled trial: a middle ground. N Engl J Med 2001, 345:915-919.
76. Vickers AJ, Craen A Why use placebo in clinical trials? A narrative review of the methodological literature. J Clin E idemiol 2000, 53:157-161.
77. Pledger GW, Hall D Active control trials: do they address the efficacy issue?. Proc Am Stat Soc 1986, 1-10.
78. Fisher LD, Gent M, Büller HR Active control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001, 141:26-32.
79. Ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3046. World Medical Association Declaration of Helsinki.
80. Cagliano S, Traversa G The use of placebo controls (correspondence). N Engl J Med 1995, 332:60.
81. AI-Khatib SM, Califf RM, Hasselblad V, et al. Placebo-controls in short-term clinical trials of hypertension. Science 2001, 292:2013-2015.
82. Alderman MH Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993, 119:329-335.
83. Temple R, Ellenberg SS Placebo controlled trials and active controlled trials in the evaluation of new treatments, part 1: ethical and scientific issues. Ann Intern Med 2000, 133:455-463.
84. Ellenberg SS, Temple R Placebo controlled trials and active-control trials in the evaluation of new treatments, part 2: practical issues and specific cases. Ann Intern Med 2000, 133:464-470.
85. American Medical Association Council on Ethical and Judicial Affairs. The use of placebo controls in clinical trials: report 2-A-1996. Chicago, 1996, American Medical Association.
86. Grof P, Akhter MI, Campbell M, et al. Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines. WHO Expert Series on Biological Psychiatry 1993, 2:28-29. Hogrefe & Huber, Seattle.
87. International ethical guidelines for biomedical research involving human subjects 1993, Council for International Organizations of Medical Sciences, Council for International Organization of Medical Sciences, Geneva.
88. Benson H, Epstein MD The placebo effect, a neglected asset in the care of patients. JAMA 1975, 232:1225-1227.
89. Roberts AH The powerful placebo revisited: magnitude of non specific effects. Mind/Body Med 1995, 1:35.
90. Drici MD, Raybaud F, DeLunardo C, et al. Influence of the behavior pattern on the nocebo response of healthy volunteers. Br J Clin Pharmacol 1995, 39:204.
91. Flynn JT Ethics of placebo use in pediatric clinical trials. The case of antihypertensive drug studies. Hypertension 2003, 42:865-869.
92. Miller FG, Emanuel EJ, Rosenstein DL, Straus SE Ethical issues concerning research in complementary and alternative medicine. JAMA 2004, 291:599-604.
93. Arnstein P The placebo effect. Sem Integr Med 2003, 1:125-135.